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INTRODUCTION
Calcium channel blockers（CCBs）, originally named 
calcium antagonists, inhibit calcium entry by interact-
ing with voltage-gated calcium channels 1）. CCBs are 
commonly used for treatment of cardiovascular disor-
ders such as hypertension and they are classified into 
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SUMMARY
Hyperuricemia has recently been recognized as one of the risk factors for cardiovascular diseases. Some 
calcium channel blockers（CCBs）, commonly used in the treatment of hypertension, have been reported to 
decrease serum urate level. Here, we tried to elucidate the molecular mechanism of the urate-lowering 
effects of CCBs. We performed ［14C］urate uptake in cells stably expressing human urate transporter 1, a 
major contributor of renal urate reabsorption and a major target of uricosuric drugs such as benzbroma-
rone and losartan（HEK-URAT1）, together with mock（HEK-mock）cells to analyze the uricosuric action 
of CCBs. We also measured the activity of human xanthine oxidase（XO）to determine whether CCBs have 
inhibitory effects on urate production. The CCBs tested were nifedipine, nilvadipine, nitrendipine, benidip-
ine, nisoldipine, nicardipine, efonidipine, amlodipine, azelnidipine, verapamil and diltiazem. We found for the 
first time that at least seven CCBs in the dihydropyridine subgroup interacted with URAT1-mediated 
urate uptake in HEK-URAT1 cells. Among these CCBs, nifedipine, nilvadipine and nitrendipine strongly 
inhibited URAT1-mediated urate uptake. Their IC50s were 15.8, 0.018 and 0.40 µM, respectively. In con-
trast, urate production mediated by XO was weakly inhibited by nifedipine and nisoldipine. In summary, 
URAT1 interacted with various CCBs differently, whereas XO, a major enzyme for urate production in the 
liver, did not interact with most of CCBs. Although CCBs were not excreted from the urine basically, their 
urate-lowering effects may be associated with the inhibition of renal urate reabsorption mediated by renal 
urate transporters such as URAT1 with their metabolites, and the results for structure-activity informa-
tion in this study will provide a clue for developing new uricosuric drugs targeting URAT1.
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several classies including the dihydropyridine sub-
group（e.g., nifedipine）and non-dihydropyridine sub-
group（e.g., verapamil and diltiazem）.
In addition to their established therapeutic uses, 
clinical studies have shown that some CCBs have uri-
cosuric actions 2〜5）. Since CCBs have vasodilatory 
effects on afferent arterioles, they induce glomerular 
filtration and, as a result, increase the clearance of 
urate, leading to a reduction of its serum level 6）. The 
anti-hypertensive drug losartan, an angiotensin II 
receptor blocker known to have an uricosuric effect, 
has been reported to inhibit renal urate reabsorption 
by interacting with tubular urate transporters 7）. How-
ever, the molecular mechanism of the urate-lowering 
effect found in CCBs is still uncertain.
In humans, serum urate level is determined by the 
balance between enzymatic production mainly in the 
liver by xanthine oxidase（XO）and urinary excretion 
mediated by renal tubular urate transporters 8）. 
Human renal urate transporter URAT1 is thought to 
be an essential molecule that mediates the initial step 
of urate reabsorption at the apical side of the proxi-
mal tubule 9）. To determine the molecular mechanism 
of the urate-lowering effects of CCBs, we examined 
their interaction with XO and renal apical urate trans-
porter URAT1 in vitro.
METHODS
Materials
［14C］urate（50 mCi/mmol）was purchased from Per-
kin Elmer Life Sciences（Boston, MA）. Nifedipine, 
nitrendipine, benidipine, nisoldipine, nicardipine, amlo-
dipine, azelnidipine, verapamil, diltiazem and benzbro-
marone were obtained from Wako Pure Chemical 
Industry Ltd.（Osaka, Japan）. Nilvadipine and azelni-
dipine were purchased from Tokyo Chemical Industry 
Co. Ltd.（Tokyo, Japan）. Efonidipine was purchased 
from Sigma Chemical Co.（St. Louis, MO）. Fetal 
bovine serum, trypsin, geneticin and Lipofectamin 
were obtained from Invitrogen（Carlsbad, CA）.
Cell culture
HEK-URAT1 cells were established according to a 
method previously described by us 10）. Briefly, the full-
length cDNA of URAT1 was subcloned into pcDNA 
3.1（Invitrogen, Carlsbad, CA）, a mammalian expres-
sion vector. HEK-URAT1 cells were obtained by 
transfecting HEK293 cells with pcDNA3.1-URAT1 
using Lipofectamin according to the manufacturer’s 
instructions. HEK293 cells transfected with pcDNA3.1 
lacking an insert were used as control（HEK-mock 
cells）. The cells were grown in a humidified incubator 
at 37℃ and in 5％ CO2 using Dulbecco’s modified 
Eagle’s medium（DMEM）supplemented with 10％ 
fetal bovine serum（FBS）, 1 mM sodium pyruvate, 100 
U/ml penicillin, 100 mg/ml streptomycin（Invitrogen）
and 400 µg/ml geneticin（SIGMA）. The cells were 
subcultured in a medium containing 0.05％ trypsin-
EDTA solution（containing in mM：137 NaCl, 5.4 KCl, 
5.5 glucose, 4 NaHCO3, 0.5 EDTA and 5 Hepes；pH 
7.2）and used for 15〜25 passages.
Uptake experiments
Uptake experiments were performed as previously 
described 11）. HEK-URAT1 and HEK-mock cells were 
seeded in 24-well tissue culture plates at a density of 
1×10 5 cells/well. After cells were cultured for 2 days, 
they were washed three times with serum- and chlo-
ride-free Hanks’ balanced salt solution（HBSS）con-
taining 125 mM Na gluconate, 4.8 mM K gluconate, 
1.2 mM KH2PO4, 1.2 mM MgSO4, 1.3 mM Ca gluconate, 
5.6 mM glucose and 25 mM HEPES, pH 7.4 and then 
preincubated in the same solution in a water bath at 
37℃ for 10 min. The cells were then incubated in the 
HBSS containing 5 µM ［14C］urate at 37℃ for the indi-
cated time. The uptake was stopped by adding ice-
cold HBSS, and the cells were washed three times 
with the same solution. The cells in each well were 
lysed with 0 .5 ml of 0 .1 N sodium hydroxide and 
2 .5 ml of INSTA-GEL PLUS（Perkin Elmer）, and 
radioactivity was determined using a b-scintillation 
counter（LSC-3100, Aloka, Tokyo, Japan）and normal-
ized to the cellular protein content measured by using 
the BCA assay（Pierce, Rockford, IL, USA）.
Inhibition study
To evaluate the inhibitory effects of various CCBs 
on urate uptake via URAT1, HEK-URAT1 cells were 
incubated in a solution containing 5 µM ［14C］urate in 
the absence or presence of various concentrations of 
drugs at 37℃ for 2 min. The drugs were dissolved in 
dimethylsulfoxide. The final concentration of dimethyl-
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sulfoxide in the incubation medium was adjusted to 
be less than 0.5％ .
Xanthine oxidase（XO）assay
A Xanthine Oxidase Fluorometric Assay Kit（Cay-
man Chemical Co.）was used to quantify xanthine oxi-
dase activity according to the instructions of the man-
ufacturer 12,13）. Urate production by XO was assessed 
in the presence or absence of allopurinol（50 µM）and 
CCBs（50 µM）.
Statistical Analysis
Data are expressed as means±S.E. Statistical differ-
ences were determined using one-way ANOVA with 
Dunnett’s post-hoc test. Differences were considered 
significant at P＜0.05.
RESULTS
Inhibitory effects of CCBs on utrate uptake mediated by 
URAT1
We elucidated the effects of CCBs on urate uptake 
mediated by HEK-URAT1 cells. As shown in Figure 
1, we tested eleven drugs including nifedipine, nilva-
dipine, nitrendipine, benidipine, nisoldipine, nicardipine, 
efonidipine, amlodipine and azelnidipine（dihydropyri-
dine subgroup）and verapamil and diltiazem（non-
Nifedipine
Amlodipine
Nitrendipine NisoldipineNilvadipine
NicardipineBenidipine Azelnidipine
DiltiazemVerapamil
Dihydropyridine subgroup
Non-dihydropyridine subgroup
Efonidipine
Benzbromarone Allopurinol
Figure 1　Chemical structures of drugs used in this study.
Go Tsuchiya26 DJMS
dihydropyridine subgroup）. Among these drugs, nife-
dipine, nilvadipine, and nitrendipine strongly inhibited 
URAT1-mediated urate uptake（47％ , 32％ , and 43
％ , respectively；Figure 2）and benidipine, nisoldip-
ine, nicardipine and efonidipine moderately inhibited 
URAT1-mediated urate uptake（60％ , 59％ , 58％ , 
and 64％ , respectively；Figure 2）. These drugs did 
not show any inhibitory effects on urate uptake in 
HEK-mock cells（data not shown）. Figure 3 shows 
the dose-dependent inhibitory effects of nifedipine（A）, 
nilvadipine（B）and nitrendipine（C）on urate uptake 
in HEK-URAT1 cells. Their IC50 values for urate 
uptake by HEK-URAT1 were 15.8, 0.018, and 0.40 
µM, respectively.
Inhibitory effects of CCBs on xanthine oxidase
We also examined the effects of CCBs on urate pro-
duction mediated by xanthine oxidase（XO）. As 
shown in Figure 4, urate production mediated by XO 
was significantly（p＜0.05）, but slightly inhibited by 
nifedipine and nisoldipine（50 µM each）, while most of 
the CCBs tested in this study did not show any inhibi-
tory effect on urate production by XO.
DISCUSSION
In this study, we examined the interaction of CCBs 
with XO and with renal apical urate transporter 
URAT1 in vitro to clarify the molecular mechanism of 
the urate-lowering effects of CCBs. URAT1, a major 
molecule for renal urate reabsorption, interacted with 
CCBs to various degree, whereas XO, a major enzyme 
for urate production in the liver, did not interact with 
CCBs.
Serum urate level in humans are determined by the 
balance between production by XO mainly in the liver 
and urinary excretion by renal proximal tubules. Sev-
eral tubular urate transporters are thought to be 
involved in urinary urate excretion. One important 
transporter is URAT1（encoded by SLC22A12）, a 
urate–anion exchanger localized at the apical side of 
the renal proximal tubule that mediates the initial 
step of urate reabsorption. The physiological impor-
tance in renal urate reabsorption of URAT1 has been 
established on the basis of the fact that several loss-
of-function mutations in SLC22A12 cause renal hyp-
ouricemia 14,15）and on the basis of results of a genome-
wide association study（GWAS）for hematological and 
biochemical traits from approximately 14,700 Japanese 
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Figure 2　 Effects of various CCBs on urate uptake mediated by HEK-URAT1 cells. 
HEK-URAT1 cells were incubated in a solution containing 5 µM ［14C］urate 
in the absence or presence of 10 µM CCBs for 2 min at 37℃ . Each value rep-
resents the mean±S.E. of eight to twelve monolayers from two separate 
experiments. ＊＊P＜0.01 vs. control.
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Figure 4　 Effects of CCBs on urate production mediated by xanthine oxidase. Urate pro-
duction was determined in the presence or absence of allopurinol（50 µM）and 
CCBs（50 µM）. Each value represents the mean±S.E. of six to nine samples 
from one typical experiment of two separate experiments. ＊P＜0.05 and ＊＊P
＜0.01 vs. control.
Figure 3　 Dose-dependent inhibition by nifedipine（A）, 
nilvadipine（B）and nitrendipine（C）on URAT1-
mediated urate uptake. HEK-URAT1 cells were 
incubated in a solution containing 5 µM ［14C］
urate in the absence or presence of nifedipine, 
nilvadipine, and nitrendipine with various concen-
tration（1 µM to 1 mM）. Each value represents 
the mean±S.E. of four monolayers from one typi-
cal experiment of two separate experiments.
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individuals 16）. In the present study, we clarified the 
interactions of URAT1 with various CCBs using 
HEK-URAT1 cells and we proposed the possible 
mechanism of the urate-lowering effects of CCBs via 
inhibition of renal urate reabsorption by interacting 
with the major urate transporter URAT1.
Using HEK-URAT1 cells that exhibited a time- and 
dose-dependent uptake of urate（data not shown）, we 
elucidated the interactions of URAT1 with CCBs 
including nifedipine, nilvadipine, nitrendipine, benidip-
ine, nisoldipine, nicardipine, efonidipine, amlodipine, 
azelnidipine, verapamil, and diltiazem. Among these 
CCBs, nifedipine, nilvadipine, and nitrendipine strongly 
inhibited URAT1-mediated urate uptake and benidip-
ine, nisoldipine, nicardipine, efonidipine moderately 
inhibited URAT1-mediated urate uptake, but the 
non-dihydropyridine subgroup did not show any 
interaction（Figure 2）. Based on their strength, we 
chose nifedipine, nilvadipine, and nitrendipine and 
checked the dose-dependency for their URAT1 inhibi-
tion. Although IC50 of nilvadipine（0.018 µM）in HEK-
URAT1 cells was comparable to Cmax in normal sub-
jects（0.009 µM）17）, the uricosuric action of nilvadipine 
targeting URAT1 is less likely to occur because its 
unbound form is not excreted into urine 17）. From this 
point of view, the urate-lowering effects of CCBs are 
not the same as that of losartan, another anti-hyper-
tensive drug that has been reported to have uricosu-
ric action. However, since more than half of their 
metabolites are excreted in urine, those that have a 
chemical structure similar to that of the original CCBs 
may interact with renal urate transporters such as 
URAT1 and provide a urate-lowering effect observed 
in several clinical studies similar to the report of inter-
action of URAT1 with benzbromarone and its metabo-
lite 6-OH-benzbromarone 18）.
The different degrees of inhibition of URAT1 by 
CCBs shown in Figure 2 provide information on the 
structure-activity relation for the development of new 
uricosuric drugs. Based on the strong inhibition by 
three drugs of the dihydropyridine subgroup（nifedip-
ine, nilvadipine and nitrendipine）, a nitrophenyl group 
at the C4-position of the dihydropyridine ring seems 
to be important for interaction with unknown binding 
site（s）of URAT1 and inducing a strong interaction.
Urate production mediated by XO was not inhibited 
by most of the CCBs tested（except nifedipine and 
nisoldipine）in this study. This means that the urate-
lowering effects of CCBs are not due to the inhibition 
of urate production. Hepatic enzymatic production by 
XO is important for the regulation of serum urate 
level in humans together with urinary excretion by 
tubular transporters, but only a limited number of 
drugs such as allopurinol and febuxostat have shown 
inhibition of XO. The urate-lowering effects of CCBs 
do not seem to be mediated by XO inhibition based 
on our results.
CONCLUSION
Using HEK-URAT1 cells, we clarified the interac-
tion of CCBs with URAT1 for the first time. Although 
the unbound forms of most CCBs were not excreted 
into urine, their urate-lowering effects may be associ-
ated with the inhibition of renal urate reabsorption 
mediated by renal urate transporters such as URAT1 
with their metabolites that may retain the similar 
chemical structure. In addition, the results of this 
study provide a useful clue for the development of 
new uricosuric drugs.
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